This invention relates generally to compounds that are glucuronidase inhibitors. The glucuronidase inhibitors include phenoxy thiophene sulfonamides, and other compounds such as pyridine sulfonyls, benzene sulfonyls, thiophene sulfonyls, thiazole sulfonyls, thiophene carbonyls, and thiazole carbonyls. These compounds include nialamide, isocarboxazid, phenelzine, amoxapine, loxapine and mefloquine. Also compositions including one or more of such compounds for use in inhibiting glucuronidase and m...

The invention relates to methods and compositions for the treatment or prevention of thrombosis, thrombus formation, a thrombotic event or complication, or a cardiovascular disease or event. In particular, the invention relates to an LSD 1 inhibitor for use in treating or preventing thrombosis, thrombus formation, a thrombotic event or complication, or a cardiovascular disease or event.

The invention relates to methods and compositions for the treatment or prevention of inflammation and inflammatory diseases or conditions. In particular, the invention relates to an LSD l inhibitor for use in treating or preventing inflammation and inflammatory diseases or conditions.

Use of at least one compound (A), preferably at least an inhibitor of aldosterone synthase (CYP11B2) comprising 4-androstene-4-ol-3,17-dio ne, 4-androstene-3,17-dione, substituted phenyl compounds (I), preferably phenelzine, pyridocarbazole compounds (II), preferably ellipticine, and/or their salts, to prepare a medicament for the treatment and/or prevention of hyperaldosteronism and/or cardiovascular disease, preferably for treatment and/or prevention of e.g. cardiac hypertrophy, and/or promoti...

PURPOSE: Pharmaceutical compositions are provided for the treatment of nicotine dependence or addiction tobacco dependence or addiction reduction of nicotine withdrawal symptoms or aiding in the cessation or lessening of tobacco use or substance abuse. CONSTITUTION: The therapeutically effective pharmaceutical combination is comprised of a nicotine receptor partial agonist and an anti-depressant or anxiolytic agent and a pharmaceutically acceptable carrier. In a more specific embodiment the anti...

1243991. CNS depressants. IMPERIAL CHEMICAL INDUSTRIES Ltd. 4 Sept. 1969 [10 June 1968] No. 27501/68. Heading A5B. [Also in Division C2] Pharmaceutical compositions suitable for oral or parenteral administration and having depressant activity on the central nervous system and thymoleptic activity contain novel piperidine piperazine or morpholine derivatives of the formula wherein A is -O- -CH 2 - or =NCOR where R is H alkyl aryl halogenoaryl alkoxy aryloxy arolkloxy or amino and X is phenyl whi...